{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:36:28Z","timestamp":1790710588160,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.psc.2019.01.007","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T02:07:24Z","timestamp":1554257244000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Pharmacologic Treatment of Eating Disorders"],"prefix":"10.1016","volume":"42","author":[{"given":"Scott J.","family":"Crow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/eat.22087","article-title":"A\u00a0cost effectiveness analysis of stepped care treatment for bulimia nervosa","volume":"46","author":"Crow","year":"2013","journal-title":"Int J Eat Disord"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00004714-198306000-00004","article-title":"A\u00a0double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa","volume":"3","author":"Gross","year":"1983","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(87)90085-0","article-title":"A\u00a0placebo-controlled crossover study of oral clonidine in acute anorexia nervosa","volume":"20","author":"Casper","year":"1987","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.psc.2019.01.007_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00004714-198111000-00005","article-title":"A\u00a0double-blind controlled trial of lithium carbonate primary anorexia nervosa","volume":"1","author":"Gross","year":"1981","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tins.2013.01.003","article-title":"Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa","volume":"36","author":"Kaye","year":"2013","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1176\/ajp.155.4.548","article-title":"Does fluoxetine augment the inpatient treatment of anorexia nervosa?","volume":"155","author":"Attia","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.01.007_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/eat.10235","article-title":"Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa","volume":"35","author":"Barbarich","year":"2004","journal-title":"Int J Eat Disord"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib8","first-page":"425","article-title":"Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls","volume":"33","author":"Strober","year":"1997","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"10.1016\/j.psc.2019.01.007_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0006-3223(00)01013-1","article-title":"Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa","volume":"49","author":"Kaye","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"22","key":"10.1016\/j.psc.2019.01.007_bib10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/jama.295.22.2605","article-title":"Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2019.01.007_bib11","unstructured":"Attia E. Presentation at the Eating Disorders Research Society annual meeting. New York: 2016."},{"key":"10.1016\/j.psc.2019.01.007_bib12","unstructured":"Attia E. Presented at the Eating Disorder Research Society annual meeting. Sydney (Australia): 2018."},{"issue":"9","key":"10.1016\/j.psc.2019.01.007_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1176\/appi.ajp.2017.16121402","article-title":"Significant locus and metabolic genetic correlations\u00a0revealed in genome-wide association study of anorexia nervosa","volume":"174","author":"Duncan","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/ajp.134.11.1249","article-title":"Phenytoin treatment of the binge-eating syndrome","volume":"134","author":"Wermuth","year":"1977","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2019.01.007_bib15","first-page":"339","article-title":"Antidepressant drug therapy for bulimia: current status","volume":"47","author":"Pope","year":"1986","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2019.01.007_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1192\/bjp.166.5.660","article-title":"Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group","volume":"166","author":"Goldstein","year":"1995","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpsyc.1992.01820020059008","article-title":"Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group","volume":"49","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/eat.10265","article-title":"A\u00a0trial of a relapse prevention strategy in women with bulimia nervosa who respond to cognitive-behavior therapy","volume":"35","author":"Mitchell","year":"2004","journal-title":"Int J Eat Disord"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/070674378803300211","article-title":"Treatment of bulimia with desipramine: a double-blind crossover study","volume":"33","author":"Barlow","year":"1988","journal-title":"Can J Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archpsyc.1986.01800020092012","article-title":"Treating bulimia with desipramine. A double-blind, placebo-controlled study","volume":"43","author":"Hughes","year":"1986","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1176\/ajp.147.11.1509","article-title":"Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study","volume":"147","author":"McCann","year":"1990","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2019.01.007_bib23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1176\/ajp.148.9.1206","article-title":"Long-term outcome of antidepressant treatment for bulimia nervosa","volume":"148","author":"Walsh","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00004714-198908000-00004","article-title":"A\u00a0placebo-controlled study of trazodone in bulimia nervosa","volume":"9","author":"Pope","year":"1989","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2019.01.007_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198510000-00005","article-title":"Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid","volume":"5","author":"Kennedy","year":"1985","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2019.01.007_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archpsyc.1988.01800290091011","article-title":"Phenelzine vs. placebo in 50 patients with bulimia","volume":"45","author":"Walsh","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v64n1109","article-title":"Treatment of bulimia nervosa with\u00a0topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures","volume":"64","author":"Hoopes","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2019.01.007_bib28","first-page":"262","article-title":"Treatment of bulimia with bupropion: a multicenter controlled trial","volume":"49","author":"Horne","year":"1988","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4088\/JCP.v63n1113","article-title":"A\u00a0placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder","volume":"63","author":"Arnold","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2019.01.007_bib30","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1176\/ajp.155.12.1756","article-title":"Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial","volume":"155","author":"Hudson","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CHI.0b013e31819996f1","article-title":"National comorbidity survey replication adolescent supplement (NCS-A): I. Background and measures","volume":"48","author":"Merikangas","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.01.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.899","article-title":"High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial","volume":"23","author":"Guerdjikova","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4088\/JCP.12m08071","article-title":"Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"White","year":"2013","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eat.20946","article-title":"Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial","volume":"45","author":"Guerdjikova","year":"2012","journal-title":"Int J Eat Disord"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/YIC.0b013e328329c7b5","article-title":"Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial","volume":"24","author":"Guerdjikova","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2019.01.007_bib36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1176\/appi.ajp.157.6.1004","article-title":"Placebo-controlled trial of sertraline in the treatment of binge eating disorder","volume":"157","author":"McElroy","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4088\/JCP.v68n0306","article-title":"Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial","volume":"68","author":"McElroy","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1176\/ajp.153.11.1455","article-title":"d-fenfluramine treatment of binge eating disorder","volume":"153","author":"Stunkard","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archpsyc.60.11.1109","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder","volume":"60","author":"Appolinario","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.01.007_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1176\/appi.ajp.2007.06121970","article-title":"Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study","volume":"165","author":"Wilfley","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.01.007_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2019.01.007_bib42","first-page":"S138","article-title":"Topiramate for the treatment of moderate to severe binge eating disorder associated with obesity: a double-blind, placebo-controlled study","volume":"30","author":"McElroy","year":"2005","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.psc.2019.01.007_bib43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4088\/JCP.v65n1104","article-title":"Topiramate in the long-term treatment of binge-eating disorder associated with obesity","volume":"65","author":"McElroy","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2019.01.007_bib44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.4088\/JCP.v67n1209","article-title":"Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial","volume":"67","author":"McElroy","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2019.01.007_bib45","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamapsychiatry.2017.1889","article-title":"Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"74","author":"Hudson","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2019.01.007_bib46","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/npp.2015.275","article-title":"Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials","volume":"41","author":"McElroy","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psc.2019.01.007_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2019.01.007_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/YCO.0000000000000454","article-title":"Cognitive-behavioral treatment of avoidant\/restrictive food intake disorder","volume":"31","author":"Thomas","year":"2018","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.01.007_bib49","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaac.2018.01.011","article-title":"Mirtazapine and weight gain in avoidant and restrictive food intake disorder","volume":"57","author":"Gray","year":"2018","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.psc.2019.01.007_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11920-017-0795-5","article-title":"Avoidant\/restrictive food intake disorder: a\u00a0three-dimensional model of neurobiology with implications for etiology and treatment","volume":"19","author":"Thomas","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.psc.2019.01.007_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eurpsy.2018.08.001","article-title":"Other specified feeding or eating disorders (OSFED): clinical heterogeneity and cognitive-behavioral therapy outcome","volume":"54","author":"Riesco","year":"2018","journal-title":"Eur Psychiatry"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X19300127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X19300127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:39:06Z","timestamp":1759282746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X19300127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0193953X19300127"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2019.01.007","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatment of Eating Disorders","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2019.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}